LON:DPH - Dechra Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: GBX 3,438.33
Forecasted Upside: -17.03 %
Number of Analysts: 3
Breakdown:
0 Sell Ratings
1 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

GBX 4,144 As of 05/7/2021 01:00 AM ET

▲ +30 (0.73%)

1 month | 3 months | 12 months

Get New Dechra Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

GBX 3,438.33

▼ -17.03% Downside Potential

This price target is based on 3 analysts offering 12 month price targets for Dechra Pharmaceuticals in the last 3 months. The average price target is GBX 3,438.33, with a high forecast of GBX 3,600 and a low forecast of GBX 3,200. The average price target represents a -17.03% upside from the last price of GBX 4,144.

Buy

The current consensus among 3 investment analysts is to buy stock in Dechra Pharmaceuticals. This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/16/2019

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/14/2020

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/14/2020

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/12/2020

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/10/2020

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/8/2021

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/9/2021

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/9/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Details
3/11/2021	Royal Bank of Canada	Boost Price Target	Sector Perform	GBX 3,450 ➝ GBX 3,600	i
7/22/2020	Jefferies Financial Group	Boost Price Target	Buy	GBX 3,185 ➝ GBX 3,515	i
6/5/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	GBX 3,300 ➝ GBX 3,200	i
6/4/2020	Royal Bank of Canada	Lower Price Target	Sector Performer	GBX 2,560 ➝ GBX 2,510	i
4/24/2020	HSBC	Boost Price Target	Hold	GBX 3,020 ➝ GBX 3,085	i
3/20/2020	Royal Bank of Canada	Boost Price Target	Sector Performer	GBX 2,530 ➝ GBX 2,560	i
3/13/2020	Royal Bank of Canada	Boost Price Target	Sector Performer	GBX 2,500 ➝ GBX 2,530	i
2/25/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	GBX 3,200 ➝ GBX 3,300	i
1/21/2020	Jefferies Financial Group	Downgrade	Hold	GBX 3,090 ➝ GBX 2,930	i
1/6/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	GBX 3,500 ➝ GBX 3,200	i
12/2/2019	HSBC	Boost Price Target	Hold	GBX 2,915 ➝ GBX 2,950	i
9/4/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	GBX 3,000 ➝ GBX 3,500	i
9/2/2019	Royal Bank of Canada	Boost Price Target	Sector Perform	GBX 2,100 ➝ GBX 2,500	i
3/25/2019	Jefferies Financial Group	Boost Price Target	Buy	GBX 2,466 ➝ GBX 2,805	i
3/25/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight	GBX 3,000	i
3/11/2019	HSBC	Lower Price Target	Buy	GBX 2,770 ➝ GBX 2,700	i
2/12/2019	HSBC	Initiated Coverage	Buy	GBX 2,770	i
11/23/2018	Royal Bank of Canada	Lower Price Target	Sector Performer	GBX 2,400 ➝ GBX 2,100	i
9/3/2018	Numis Securities	Downgrade	Hold		i
7/10/2018	Numis Securities	Boost Price Target	Add	GBX 2,640 ➝ GBX 2,950	i
2/26/2018	Royal Bank of Canada	Reiterated Rating	Sector perform	GBX 2,400	i
2/26/2018	Numis Securities	Reiterated Rating	Add	GBX 2,640	i
2/2/2018	Numis Securities	Reiterated Rating	Add	GBX 2,640	i
2/1/2018	Royal Bank of Canada	Downgrade	Sector Performer	GBX 2,200 ➝ GBX 2,400	i
1/30/2018	Jefferies Financial Group	Upgrade	Buy	GBX 2,221 ➝ GBX 2,631	i
1/18/2018	Numis Securities	Reiterated Rating	Add	GBX 2,260	i
1/17/2018	Jefferies Financial Group	Reiterated Rating	Hold	GBX 2,221	i
9/5/2017	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,565 ➝ GBX 1,868	i
7/11/2017	Stifel Nicolaus	Reiterated Rating	Hold	GBX 1,550	i
7/6/2017	Investec	Reiterated Rating	Buy	GBX 1,840	i
7/6/2017	N+1 Singer	Reiterated Rating	Buy	GBX 1,666	i
7/6/2017	Numis Securities	Reiterated Rating	Add	GBX 1,890	i
4/20/2017	Panmure Gordon	Reiterated Rating	Under Review		i
4/4/2017	Numis Securities	Boost Price Target	Add	GBX 1,700 ➝ GBX 1,890	i
4/4/2017	Stifel Nicolaus	Boost Price Target	Hold	GBX 1,440 ➝ GBX 1,550	i
3/14/2017	Royal Bank of Canada	Boost Price Target	Outperform	GBX 1,630 ➝ GBX 1,890	i
3/1/2017	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,320 ➝ GBX 1,565	i
2/27/2017	N+1 Singer	Reiterated Rating	Buy	GBX 1,600	i
2/27/2017	Numis Securities	Reiterated Rating	Add	GBX 1,700	i
2/24/2017	FinnCap	Reiterated Rating	Under Review		i
1/26/2017	Panmure Gordon	Reiterated Rating	Under Review		i
1/17/2017	Numis Securities	Reiterated Rating	Add	GBX 1,520	i
1/17/2017	Panmure Gordon	Reiterated Rating	Under Review		i
12/15/2016	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,295 ➝ GBX 1,320	i
11/29/2016	FinnCap	Reiterated Rating	Under Review		i
10/27/2016	Numis Securities	Reiterated Rating	Add	GBX 1,520	i
10/21/2016	N+1 Singer	Boost Price Target	Buy	GBX 1,350 ➝ GBX 1,412	i
10/21/2016	Stifel Nicolaus	Reiterated Rating	Hold	GBX 1,250	i
9/16/2016	N+1 Singer	Reiterated Rating	Buy	GBX 1,350	i
9/11/2016	Panmure Gordon	Reiterated Rating	Buy	GBX 1,140	i
9/9/2016	N+1 Singer	Lower Price Target	Buy	GBX 1,350	i
9/7/2016	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,229 ➝ GBX 1,295	i
9/5/2016	Investec	Boost Price Target	Buy	GBX 1,300 ➝ GBX 1,400	i
9/5/2016	Stifel Nicolaus	Reiterated Rating	Hold	GBX 1,250	i
9/5/2016	Jefferies Financial Group	Reiterated Rating	Hold	GBX 1,300	i
9/5/2016	Panmure Gordon	Reiterated Rating	Buy	GBX 1,140	i
9/5/2016	Numis Securities	Reiterated Rating	Add	GBX 1,320	i
8/30/2016	FinnCap	Reiterated Rating	Under Review		i
8/17/2016	Numis Securities	Reiterated Rating	Add	GBX 1,320	i
7/26/2016	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,189 ➝ GBX 1,229	i
7/12/2016	Numis Securities	Reiterated Rating	Add	GBX 1,320	i
6/30/2016	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,099 ➝ GBX 1,189	i
6/24/2016	Numis Securities	Reiterated Rating	Add	GBX 1,285	i
6/3/2016	Jefferies Financial Group	Downgrade	Hold	GBX 1,140 ➝ GBX 1,099	i

(Data available from 5/9/2016 forward)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Today's Range

Now: GBX 4,144

4,060

4,158

50 Day Range

MA: GBX 3,689.12

3,382

4,144

52 Week Range

Now: GBX 4,144

2,552

4,853.46

Volume

178,415 shs

Average Volume

216,793 shs

Market Capitalization

£4.48 billion

P/E Ratio

100.10

Dividend Yield

0.85%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dechra Pharmaceuticals?

The following Wall Street research analysts have issued reports on Dechra Pharmaceuticals in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for DPH.

What is the current price target for Dechra Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Dechra Pharmaceuticals in the last year. Their average twelve-month price target is GBX 3,438.33, suggesting a possible downside of 17.0%. Royal Bank of Canada has the highest price target set, predicting DPH will reach GBX 3,600 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 3,200 for Dechra Pharmaceuticals in the next year.
View the latest price targets for DPH.

What is the current consensus analyst rating for Dechra Pharmaceuticals?

Dechra Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DPH will outperform the market and that investors should add to their positions of Dechra Pharmaceuticals.
View the latest ratings for DPH.

What other companies compete with Dechra Pharmaceuticals?

Other companies that are similar to Dechra Pharmaceuticals include Hutchison China MediTech, Vectura Group, Beximco Pharmaceuticals, ECO Animal Health Group, Allergy Therapeutics, Futura Medical, Trilogy International Partners, Sareum Holdings plc (SAR.L), Avivagen, N4 Pharma, Cathay International Holdings Limited (CTI.L), Antisense Therapeutics, Bayer Aktiengesellschaft, Mayne Pharma Group and Mayne Pharma Group.

How do I contact Dechra Pharmaceuticals' investor relations team?

Dechra Pharmaceuticals' physical mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company's listed phone number is +44-1606-814730. The official website for Dechra Pharmaceuticals is www.dechra.com.